



## Narrative review

Contaminants in blood cultures: importance, implications, interpretation and prevention<sup>☆</sup>S. Dargère<sup>1,\*</sup>, H. Cormier<sup>1</sup>, R. Verdon<sup>1,2</sup><sup>1</sup>) CHU de Caen, Service de Maladies Infectieuses et Tropicales, Caen, France<sup>2</sup>) Normandie University, UNICAEN, UNIROUEN, GRAM, Caen, France

## ARTICLE INFO

## Article history:

Received 24 December 2017

Received in revised form

17 March 2018

Accepted 20 March 2018

Available online 3 April 2018

Editor: L. Leibovici

## Keywords:

Blood culture contaminations

Blood cultures

Coagulase-negative staphylococci

Contaminants

Prevention

## ABSTRACT

**Background:** Despite the development of new microbiologic technologies, blood cultures (BCs) remain the first-line tool for the diagnosis of bloodstream infections. Their diagnostic value may be affected when a microorganism of questionable evidence is isolated—for example, coagulase-negative staphylococci, *Bacillus* spp., viridans group streptococci, *Corynebacterium* spp., *Propionibacterium* spp. and *Micrococcus* spp. Finally, making a correct diagnosis of pathogenicity (vs. contamination) is challenging. **Aims:** To review the current ways of dealing with the problem of BC contaminants (BCCs) and to provide practical suggestions to decrease BCC rates.

**Sources:** PubMed electronic databases and existing reviews were searched up to December 2017 to retrieve relevant publications related to the topic.

**Contents:** This review describes the burden of BCC and analyses the main current issues and controversies in interpreting the occurrence of potential BC contaminants. It focuses on the best-described approaches to decide whether BCC is present and discusses the different strategies of prevention in adults.

**Implications:** Each institution should have an efficient policy to prevent BCC, emphasizing the importance of following guidelines for prescribing and collecting BCs. Training healthcare workers should focus on detrimental influence on patient care and highlight the work and costs due to contaminants. The accurate differentiation of a contaminant from a true pathogen relies on a multidisciplinary approach and the clinical judgement of experienced practitioners. **S. Dargère, Clin Microbiol Infect 2018;24:964**

© 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

## Introduction

Blood culture (BC) remains the reference standard for the diagnosis of bloodstream infections (BSIs), but contaminations represent up to 50% of positive BCs [1,2]. A contaminant is defined as a microorganism that is supposed to be introduced into the culture during either specimen collection or processing and that is not pathogenic for the patient. The most frequently isolated microorganisms are coagulase-negative staphylococci (CNS) in 75% to

88% of contaminated BCs, followed by *Bacillus* spp., viridans group streptococci, *Corynebacterium* spp., *Propionibacterium* spp., *Micrococcus* spp. and *Clostridium perfringens* [3,4].

Differentiating a contaminant from a true pathogen is challenging because some of these microorganisms are an increasing source of true bacteraemia, especially in patients with prosthetic devices or catheters. On the basis of prevalence data, it has been recommended that BC contamination (BCC) rates should not exceed 3% of BCs performed, which is considered the standard benchmark [5]. This threshold of 3% is arbitrary and, as described in a recent review, it is possible to further reduce the BCC rate, especially by implementing appropriate blood collection procedures [6].

Here we review the current knowledge dealing with the best ways to distinguish contaminants from true pathogens and to reduce BCCs in order to lower their clinical and financial consequences.

<sup>☆</sup> Presented in part at the European Society of Clinical Microbiology and Infectious Diseases Postgraduate Education Course: Improving the Diagnosis of Bloodstream Infections—Advancing Technology and Quality for Better Care, 28–31 March 2018, Nice, France.

\* Corresponding author. S. Dargère, Service de Maladies Infectieuses, CHU Côte de Nacre, 14033 Caen Cedex, France.

E-mail address: [dargere-s@chu-caen.fr](mailto:dargere-s@chu-caen.fr) (S. Dargère).

## Methods

A comprehensive search on PubMed was conducted up to December 2017, with results limited to English-language reports. The terms in the search used in different combinations were as follows: 'contaminants,' 'blood culture contamination,' 'blood cultures' and 'coagulase negative staphylococci AND bacteraemia.' The studies reviewed were observational studies, case series, smaller trials, randomized trials, cost analyses, guidelines, meta-analyses and literature reviews.

## Importance of BCC

### *Prevalence and factors influencing BCC*

The prevalence of BCC varies from 0.6% to 17% of BCs performed [4,7–11]. Such variations may be explained by the sampling conditions and the definition of contamination itself. Factors influencing BCC rates depend on the hospital, the staff and the type of patients. Higher rates were reported in teaching hospitals, especially in emergency departments (EDs) [4,12,13]. Rapid staff turnover, lack of ongoing training and workload may contribute to this phenomenon [12,13]. Age, patient comorbidities and triage level have also been found to be associated with BCC [12–14].

### *Clinical consequences and financial burden*

Patients with contaminated BC need more consultations and more hospital admissions [1,15]. Unnecessary antibiotics are prescribed in 40% to 50% of cases, leading to a 39% increase in charges [1,11,16]. Additional costs associated with unnecessary treatments and additional charges per contaminant in adults were estimated to be \$1000 and \$8000, respectively [11,17,18]. The annual additional costs reached \$2 000 000, and the length of hospital stay was increased from 1 day to 5.4 days [1,17,18]. Lowering BCC rates leads to annual cost savings ranging from \$250 000 to \$4 100 000 [17,18].

## Interpretation of BCC: issues and controversies

### *Origin of BCC*

Contaminations are attributed to the transfer of microorganisms from the immediate environment of the patient or, more rarely, from healthcare workers' hands [19]. The diversity of CNS of the skin flora suggests that they come from several sources (e.g. stratum corneum, contiguous area, clothing and skin of other humans), but after antiseptic treatment, the repopulation of the site occurs with the same strain in favour of a reservoir not reached by topical antiseptics [20]. More than 20% of the skin flora may be beyond the reach of disinfection because microorganisms are located in pilosebaceous units and at other sites where lipids and superficial cornified epithelia protect them [21]. These data suggest that BCC may be due to a defective antiseptics. They also suggest that incompletely sterilized skin fragments are dislodged by venipuncture.

### *Methods for classification of contaminants*

The usual clinical definition of BCC is based on the opinion of skilled physicians and corresponds to the low likelihood that the microorganism isolated would be the cause of infection. Another approach is to define a contamination as a pattern of laboratory results when a microorganism from the skin is isolated. The College of American Pathologists (CAP) defines a BC set as a blood sample collected from a single venipuncture and then inoculated into one

aerobic and one anaerobic bottle. The CAP uses the single blood draw definition of BCC as the presence of one or more of the following organisms found in only one BC set and only one of a series of two or three BC sets: CNS, *Micrococcus* spp., viridans group streptococci, *Propionibacterium acnes*, *Corynebacterium* spp. and *Bacillus* spp [22].

Below we present several clues that may help differentiate BCC from true bacteraemia, as well as their reliability in the interpretation of clinical significance of the microorganism.

### *Identity of microorganism*

Predictive multivariate models showed that the identity of microorganism was the most important predictor [1]. Certain microorganisms should almost always represent true pathogens when isolated, while other organisms have been found to represent contaminants. CNS, *Micrococcus* spp., viridans group streptococci, *Propionibacterium acnes* (*Cutibacterium acnes*), *Corynebacterium* spp., *Clostridium perfringens* and *Bacillus* spp. are the organisms most commonly described as contaminants [3,4]. More anecdotally, *Enterococcus* spp., *Abiotrophia/Granulicatella* spp., *Lactobacillus* spp., *Enterobacter* spp. and other Gram-negative bacteria have been reported as contaminants [3,12,16,18]. CNS as well as *Corynebacterium jeikeium* and *Cutibacterium acnes* have emerged as pathogens of healthcare-associated infections [23,24]. They are an increasing source of central venous line-associated infection [24,25], prosthetic joint infection [26], infectious endocarditis involving prosthetic valve or implantable cardiac stimulators [27,28] and other implanted foreign devices (e.g. central nervous system) [24]. The identity of the microorganism is probably the first and most important factor that influences the physician's decision. Nevertheless, it is not possible to diagnose BCC only on the basis of identity of the microorganism, especially when a CNS is isolated.

### *Number of positive culture sets*

In a review of 500 episodes of bacteraemia, when an initial two-bottle set (e.g. one aerobic and one anaerobic bottle) was contaminated, the probability that the subsequent sets would be positive was very low [29]. Even though contaminants were detected in subsequent BCs, they were almost different from those isolated first. A mathematical model has been developed in order to help clinicians to make a decision when a CNS was isolated from BC, taking into account the number of positive two- or three-bottle sets. For samples obtained by venipuncture, the positive predictive value (PPV) was 55% for one positive BC set from one performed, 20% for one positive from two performed and 5% for one positive from three performed [30]. In this study, the PPV was 98% for two positive BC sets from two performed and 90% for two positive from three performed. The number of positive BC sets within a 24-hour period has proved to be a useful aid in interpreting the clinical significance of the isolated microorganism. Such a rule should be used cautiously when appropriate conditions are followed (skin disinfection, adequate volume for each bottle, at least two to four BC sets including aerobic and anaerobic bottles) [31]. Unfortunately, solitary BCs (i.e. only one set) are frequent (ranging from 10% to 30% of BC performed), making this difficult to apply in case of microorganisms of questionable evidence [32–35]. The interpretation of a positive solitary BC as contaminated is facilitated in a few situations (e.g. they have been taken during a febrile episode of spontaneous resolution, the patient had symptoms which were in relation to a focal infection due to other microorganisms or a noninfectious diagnosis has been established), but in cases of patients with foreign devices (e.g. central venous catheter, joint implant or prosthetic heart valve), the task is challenging. Before ruling out true bacteraemia in such patients with a positive solitary BC, special attention should be paid to factors that

may cause doubt about the quality of BC sampling (e.g. previous antibiotic therapy, insufficient blood volume in bottle).

#### *Number of positive BC bottles within a set*

Increasing the number of positive bottles within a set helps to predict the likelihood of true bacteraemia, especially when a CNS is isolated [36,37]. In a prospective study of the single-sampling strategy (SSS), an association between the number of positive bottles within a six-bottle set and the clinical significance of the organism has been demonstrated [38]. Most often, contaminants were isolated from the first (>90%) or second bottles. Considering CNS, the PPV for true bacteraemia was 3.5%, 61%, 78.9% and 100% when one, two, three and four or more bottles were positive respectively. The most difficult cases to interpret were those with two or three positive bottles, which represented only 5% of patients. The number of positive BC bottles within a set may be useful to interpret the clinical significance of microorganisms in institutions where the SSS is implemented. So when a CNS or another possible contaminant is isolated from one or two bottles within a four- or six-bottle set, it is likely that it should be considered as a contaminant. Like the multisampling strategy (MSS), the sensitivity of this technique depends on the volume of blood cultured, and it is important to underline that it needs to be validated for the diagnosis of infectious endocarditis [31].

#### *Time to growth*

It makes sense to think that the bacterial inoculum in a true bacteraemia is higher than in a BCC and grows faster. When a CNS is isolated, a growth time more than 20 hours is usually considered in favour of a contaminant [39,40]. Prior administration of antibiotics, volume of blood sample, delay of sample transfer and interval of BC review are factors that reduce the reliability of this parameter. Moreover, growth times between contaminants and true pathogens overlap [39,40]. Nowadays, even though it may be affected by blood volume inoculated into BC bottle, the increasing performance of incubator systems reduces the time to detection. Although the time to detection of CNS is still longer than that of other microorganisms (e.g. *Enterobacteriaceae*, *Staphylococcus aureus*, viridans group streptococci), the threshold of 20 hours to consider a CNS as a contaminant should be revised [41]. Moreover, the development of new technologies for detection of microorganisms in whole blood makes this clue obsolete.

#### *Phenotyping, genotyping profile and new microbiologic technologies*

Comparing the susceptibility testing of CNS isolated from different BCs has been shown to be highly predictive of strain relatedness; conversely, microorganisms are frequently genetically unrelated in contaminations [42]. Pulsed-field gel electrophoresis is a powerful tool to distinguish contaminant from pathogen CNS, and genotyping diversity has been described in BCC [43,44]. Despite this, molecular typing correlated poorly with clinical criteria of BSI, and this technique is not realistic in routine practice [45]. Identifying virulence markers of *Staphylococcus epidermidis* isolated from BCs to predict its clinical significance was unsuccessful [46]. More recently, it has been shown that despite the same antibiotic type there were different CNS genotypes, indicating that only rapid molecular methods can provide proof [47]. Although highly effective in distinguishing between strains of CNS isolated from BCs, this method is still expensive and time consuming.

Over the last few decades, several molecular methods have been developed for the detection of microorganisms in whole blood. Using specific targets (i.e. SeptiFast, VYOO and Magicplex) or universal/conserved targets (i.e. SepsitTest, PCR with ESI-MS mass spectrometry) for the detection of a broad range of microorganisms, these PCR-based methods circumvent the culture step and

reduce the turnaround time of microbial diagnosis [48]. However, the limited correlation between identification obtained by these molecular methods and BC-based methods, the sensitivity of these new technologies to contamination and the lack of interventional study do not allow an estimation of their impact on the classification of a microorganism isolated from blood as a contaminant.

Few reports investigated the effect of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) on the management of BCs positive for CNS [49,50]. Compared to the conventional processing, MALDI-TOF MS resulted in a decreased duration of inappropriate antimicrobial therapy but did not decrease the mean time to identify a BC as contaminated [50]. Moreover, these new technologies were always evaluated in association with an antimicrobial stewardship program; the role of MALDI-TOF MS itself in decreasing the duration of inappropriate antimicrobial therapy remains to be proved.

#### *Algorithms and clinical judgement*

On the basis of the identity of microorganism and the number of positive BCs, acceptable laboratory-based algorithms have been provided [51]. Because the interpretation of BCs positive for CNS (and other potential contaminants) is challenging, the most recent algorithms have tried to identify key points that may help in clinical practice: (a) when suspecting a false-positive BC, the microbiologist should communicate personalized information to the clinician and should avoid providing antimicrobial susceptibility testing in order to limit unnecessary antimicrobial therapy [51]; (b) the microbiologist and the clinician have to take into account the clinical status of the patient at the moment of the microbiologic diagnosis, clinical evidence of infection and the presence of foreign device (e.g. central line, prosthetic joint, implantable cardiac device) [51–53]; and (c) additional blood samples positive for the same organism in a 5- to 7-day period are an additional argument in favour of a true bacteraemia [52,53].

These algorithms were studied in heterogeneous populations, and even though they had an acceptable specificity, their PPV and negative predictive value should be assessed in specific populations [52,53].

The clinical judgement that varies with the experience of the physician is important. For example, in a recent study the clinical decision about significance of BCs positive for CNS differed significantly from the criteria of BSI recommended by the US Centers for Disease Control and Prevention, as clinicians considered patients with comorbidities, foreign devices, recent operation, at least two positive culture sets, more than two positive bottles within a set and lower time to growth, to have a true bacteraemia [54]. The recognition of a potential contaminant isolated from a BC as a contaminant is easier when the microorganism causing the sepsis is different and already identified when there is an evident focus and when the patient recovers despite not receiving specific treatment.

#### **Prevention**

There are several steps in the process of decreasing BCC.

##### *Blood sample*

##### *Antisepsis*

The literature review identified many studies focusing on the skin antisepsis, but few studies were randomized. In a meta-analysis of six clinical trials, alcoholic solutions were more effective than nonalcoholic solutions, and 2% alcoholic chlorhexidine gluconate (CHG) was found to be more effective than nonalcoholic povidone-iodine (PVI). Iodine tincture was not superior to PVI, alcoholic iodine

was not different from nonalcoholic iodine, alcohol alone was not inferior to any iodine products and the difference between CHG and iodine compounds was not conclusive [55]. More recently, a randomized trial comparing the effectiveness of three skin antiseptics (10% aqueous PVI, 2% iodine tincture and 2% alcoholic CHG) found that the choice of the product did not affect the BCC rate when phlebotomists collected blood samples for culture [56]. The low basal rate of contamination (0.76%) and the use of phlebotomy carts may have biased the results. Other authors did not find any significant difference between the BCC rates comparing CHG to 2% iodine tincture [57] or alcohol alone to 2% alcoholic CHG [58]. It is difficult to make a recommendation because some of these studies lacked power, and compliance with BC sampling guidelines was not evaluated. Alcoholic solutions appear to be better than nonalcoholic products as skin antiseptics in preventing BCC. Guidelines most often recommend using 2% alcoholic CHG solution, respecting the drying time (30 seconds) and disinfecting the top of the bottle with the same product [59–61].

Hand hygiene with alcohol-based sanitizer is recommended, and nonsterile gloves must be worn [62].

#### *Venipuncture vs. catheter draw*

In EDs, before care is provided, an intravenous catheter is often placed, and thereafter blood samples are drawn for culture. A meta-analysis including nine studies showed that the contamination rate was lower when blood samples were taken via venipuncture compared to a catheter [63]. A recent study confirmed that the relative risk of contamination for culture in samples collected via a catheter compared with venipuncture was increased [64]. The difference between the two procedures decreases when blood collection is performed through a newly inserted catheter [65].

#### *Commercial kits*

In a meta-analysis, Snyder et al. [63] were not able to make recommendations for or against prepackaged kits. Self et al. [66,67] demonstrated that when sterile kits were used, BCC rates were reduced from 4.3% with usual care to 1.7%, with an estimated annual net saving of \$483 219, which is difficult to extrapolate elsewhere in the world.

#### *Phlebotomy team*

In the United States, BC is not considered a routine procedure, and it has been shown that BCC is lower when phlebotomists collect blood samples compared to other healthcare workers [56,63,67]. In a recent study with the intervention of phlebotomists, the annual savings were approximately \$290 000 [67]. Phlebotomists are not available everywhere, but it has been demonstrated that specifically educated or motivated nurses could also have low BCC rates [68].

#### *Educational intervention*

A significant decline in BCC rates has been noted after implementation of educational interventions to reach medical and nursing staffs [66–72]. It is recommended to focus on the detrimental influence of contaminants on care; to highlight the work and costs created by contaminants; and to establish protocols for appropriate BC sampling, proposing clinical skills tests, workshops, posters, video demonstrations and simulation practice.

#### *Initial specimen diversion technique*

Needle changing showed significant reduction in BCC, although healthcare workers are at risk of needle injury. Vacuum-activated transfer devices are now available, and guidelines recommend that blood samples for culture be drawn separately from other blood collection tubes, or that blood for culture inoculation be

drawn first [73]. Assuming that the contamination may be due to colonized skin fragments that are dislodged by venipuncture, a few studies have demonstrated a reduction of 30% to 50% in contaminants when the first few millilitres (0.5–2 mL) of blood are discarded in a tube before BC collection [74,75]. Specific marketed devices for the initial specimen diversion technique have shown that they may contribute to a decrease in BCC rates in the ED [76]. This study, which was supported by the manufacturer of the device, compared this technique to phlebotomy via syringe and subsequent transfer of blood to culture vials, which may increase the contamination rate. This interesting strategy to reduce BCC needs to be evaluated in a large randomized study.

#### *Ordering BCs*

Another step to decrease BCC is to avoid opportunities to isolate a contaminant. Physicians frequently overestimate the likelihood of bacteraemia [77]. The Infectious Diseases Society of America has provided recommendations for BC collections in several infections, but many guidelines do not [73]. Many models for predicting bacteraemia have been developed in specific populations or for specific settings, but it is hard to implement them in clinical practice [78].

#### *Sampling strategy*

Sampling an adequate volume of blood is the most important parameter for the detection of BSI. It can be achieved either by increasing the number of venipunctures (MSS) or by collecting a large volume through the SSS [31]. As specified above and despite the recommendations, the MSS is associated with a high proportion of solitary BCs, mainly in the ED. This situation makes it difficult to interpret the isolation of certain microorganisms. We have to improve the ordering process of the MSS or use an alternative strategy, such as SSS. A forcing function in the computerized BC ordering process combined with an education intervention has demonstrated that solitary BC rates were decreased from 41% to 11.6% [35]. In this study, two sets of labels were systematically printed out when BCs were ordered and served as a reminder to draw one additional BC set. Despite this, each venipuncture required from the MSS remains an opportunity for contamination.

By inoculating a single sample of 40 mL (i.e. one venipuncture of four bottles) of blood instead of 30 mL, Arendrup et al. [79] showed that the increased yield of true bacteraemia was 4.2%. When they analysed BCs positive for CNS and the number of positive bottles within a set, most cases of contaminants were isolated from one or two bottles of the four-bottle set. Using a probabilistic approach, Lamy et al. [80] confirmed that the best strategy for BC sampling is one venipuncture of a six-bottle set with a specificity of 97.5% and a very good sensitivity. Considering the numbers of pathogens missed and contaminants, Dargère et al. [81], in a prospective multicentre study, demonstrated that the SSS was superior to the MSS. When the process yielded a contaminant, it was isolated from one or two bottles of the four-bottle set in 92% of cases. Clinical studies demonstrated that there was a positive correlation between the number of positive culture bottles and the recovery of a clinically significant microorganism [79,81], but large prospective studies are needed to validate the ability of the SSS to decrease the BCC rate as well as increase the yield in true bacteraemia. Moreover, comparing the SSS vs. MSS should take into account the impact of new molecular microbiologic detection methods.

#### **Conclusion**

There is growing evidence that BCC is responsible for unnecessary and costly treatment or investigations. Several studies have



tried to address two main issues: identifying BCC among positive BCs and reducing the risk of contaminating the blood sample for culture. This review shows that there is no single solution to these problems. The development of rapid molecular methods will permit earlier identification but will need to be weighed against a careful clinical analysis of the conditions of sampling, the search for an alternative diagnosis and the patient's risk factor by poorly pathogenic bacteria. The antibiotic stewardship and educational programs may provide such analyses, thereby decreasing the additional costs associated with contaminants. To reduce the risk of contamination at the time of blood sampling, a rigorous implementation of guidelines should be combined with strategies to avoid unnecessary venipuncture. A bundle of measures that take all these parameters into account might be helpful and should be prospectively investigated in order to reach BCC rates below 3%.

## Acknowledgements

This postgraduate course was supported by European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Bloodstream Infections and Sepsis, ESCMID Study Group for Staphylococci and Staphylococcal Diseases, ESCMID Study Group for Epidemiological Markers, ESCMID Study Group for Genomic and Molecular Diagnostics and ESCMID Fungal Infections Study Group.

## Transparency declaration

All authors report no conflicts of interest relevant to this article.

## References

- [1] Bates DW, Goldman L, Lee TH. Contaminant blood cultures and resource utilization. The true consequences of false-positive results. *JAMA* 1991;265:365–9.
- [2] Salluzzo R, Reilly K. The rational ordering of blood cultures in the emergency department. *Qual Assur Util Rev* 1991;6:28–31.
- [3] Weinstein MP, Towns ML, Quartey SM, Mirrett S, Reimer LG, Parmigiani G, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. *Clin Infect Dis* 1997;24:584–602.
- [4] Schiffman RB, Strand CL, Meier FA, Howanitz PJ. Blood culture contamination: a College of American Pathologists Q-Probes study involving 640 institutions and 497134 specimens from adult patients. *Arch Pathol Lab Med* 1998;122:216–21.
- [5] Clinical and Laboratory Standards Institute (CLSI). Principles and procedures for blood cultures: approved guideline. Wayne, PA: Clinical and Laboratory Standards Institute; 2007. CLSI document M47-A.
- [6] Dawson S. Blood culture contaminants. *J Hosp Infect* 2014;87:1–10.
- [7] Altindis M, Koroglu M, Demiray T, Dal T, Ozdemir M, Sengil AZ, et al. A multicenter evaluation of blood culture practices, contamination rates, and the distribution of causative bacteria. *Jundishapur J Microbiol* 2016;9: e29766.
- [8] Bekeris LG, Tworek JA, Walsh MK, Valenstein PN. Trends in blood culture contamination: a College of American Pathologists Q-Tracks study of 356 institutions. *Arch Pathol Lab Med* 2005;129:1222–5.
- [9] Harvey DJ, Albert S. Standardized definition of contamination and evidence-based target necessary for high-quality blood culture contamination rate audit. *J Hosp Infect* 2013;83:265–6.
- [10] Shin JH, Song SA, Kim MN, Lee NY, Kim EC, Kim S, et al. Comprehensive analysis of blood culture performed at nine university hospitals in Korea. *Korean J Lab Med* 2011;31:101–6.
- [11] Souvenir D, Anderson Jr DE, Palant S, Mroch H, Askin S, Anderson J, et al. Blood cultures positive for coagulase-negative staphylococci: antisepsis, pseudobacteremia, and therapy of patients. *J Clin Microbiol* 1998;36:1923–6.
- [12] Halverson S, Malani PN, Newton DW, Habicht A, Vander Have K, Younger JG. Impact of hourly emergency department patient volume on blood culture contamination and diagnostic yield. *J Clin Microbiol* 2013;51:1721–6.
- [13] Lee CC, Lee NY, Chuang MC, Chen PL, Chang CM, Ko WC. The impact of overcrowding on the bacterial contamination of blood cultures in the ED. *Am J Emerg Med* 2012;30:839–45.
- [14] Chang CJ, Wu CJ, Hsu HC, Wu CH, Shih FY, Wang SW, et al. Factors associated with blood culture contamination in the emergency department: critical illness, end-stage renal disease, and old age. *PLoS One* 2015;10, e0137653.
- [15] van der Heijden YF, Miller G, Wright PW, Shepherd BE, Daniels TL, Talbot TR. Clinical impact of blood cultures contaminated with coagulase-negative staphylococci at an academic medical center. *Infect Control Hosp Epidemiol* 2011;32:623–5.
- [16] Lee CC, Lin WJ, Shih HI, Wu CJ, Chen PL, Lee HC, et al. Clinical significance of potential contaminants in blood cultures among patients in a medical center. *J Microbiol Immunol Infect* 2007;40:438–44.
- [17] Alahmadi YM, Aldeyab MA, McElnay JC, Scott MG, Darwish Elhajji FW, Magee FA, et al. Clinical and economic impact of contaminated blood cultures within the hospital setting. *J Hosp Infect* 2011;77:233–6.
- [18] Gander RM, Byrd L, DeCrescenzo M, Hirany S, Bowen M, Baughman J. Impact of blood cultures drawn by phlebotomy on contamination rates and health care costs in a hospital emergency department. *J Clin Microbiol* 2009;47:1021–4.
- [19] Viagappan M, Kelsey MC. The origin of coagulase-negative staphylococci isolated from blood cultures. *J Hosp Infect* 1995;30:217–23.
- [20] Brown E, Wenzel RP, Hendley JO. Exploration of the microbial anatomy of normal human skin by using plasmid profiles of coagulase-negative staphylococci: search for the reservoir of resident skin flora. *J Infect Dis* 1989;160:644–50.
- [21] Selwyn S, Ellis H. Skin bacteria and skin disinfection reconsidered. *Br Med J* 1972;1:136–40.
- [22] Alcorn K, Meier FA, Schiffman RB. Blood culture contamination. Q-Tracks 2013 monitor instructions. Northfield, IL: College of American Pathologists; 2013.
- [23] Beekmann SE, Diekmann DJ, Doern GV. Determining the clinical significance of coagulase-negative staphylococci isolated from blood cultures. *Infect Control Hosp Epidemiol* 2005;26:559–66.
- [24] Hitzgenbichler F, Simon M, Salzberger B, Hanses F. Clinical significance of coagulase-negative staphylococci other than *S. epidermidis* blood stream isolates at a tertiary care hospital. *Infection* 2017;45:179–86.
- [25] Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. *Infect Control Hosp Epidemiol* 2013;34:1–14.
- [26] Tsaras G, Osmon DR, Mabry T, Lahr B, St Sauveur J, Yawn B, et al. Incidence, secular trends, and outcomes of prosthetic joint infection: a population-based study, Olmsted County, Minnesota, 1969–2007. *Infect Control Hosp Epidemiol* 2012;33:1207–12.
- [27] Chu VH, Miro JM, Hoen B, Cabell CH, Pappas PA, Jones P, et al. Coagulase-negative staphylococcal prosthetic valve endocarditis—a contemporary update based on the International Collaboration on Endocarditis: prospective cohort study. *Heart* 2009;95:570–6.
- [28] Athan E, Chu VH, Tattavin P, Seltun-Suty C, Jones P, Naber C, et al. Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. *JAMA* 2012;307:1727–35.
- [29] Weinstein MP, Reller LB, Murphy JR, Lichtenstein KA. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. *Rev Infect Dis* 1983;5:35–53.
- [30] Tokars JL. Predictive value of blood cultures positive for coagulase-negative staphylococci: implications for patient care and health care quality assurance. *Clin Infect Dis* 2004;39:333–41.
- [31] Lamy B, Dargère S, Arendrup MC, Parienti JJ, Tattavin P. How to optimize the use of blood cultures for the diagnosis of bloodstream infections? A state-of-the-art. *Front Microbiol* 2016;7:697.
- [32] Neves L, Marra AR, Camargo TZ, dos Santos MC, Zulin F, da Silva PC, et al. Correlation between mass and volume of collected blood with positivity of blood cultures. *BMC Res Notes* 2015;8:383.
- [33] Novis DA, Dale JC, Schiffman RB, Ruby SG, Walsh MK. Solitary blood cultures: a College of American Pathologists Q-Probes study of 132,778 blood culture sets in 333 small hospitals. *Arch Pathol Lab Med* 2001;125:1290–4.
- [34] Vitrat-Hinckly V, François P, Labarère J, Recule C, Stahl JP, Pavese P. Appropriateness of blood culture testing parameters in routine practice. Results from a cross-sectional study. *Eur J Clin Microbiol Infect Dis* 2011;30:533–9.
- [35] Choi J, Ensafi S, Chartier LB, Van Praet O. A quality improvement initiative to decrease the rate of solitary blood cultures in the emergency department. *Acad Emerg Med* 2017;24:1080–7.
- [36] Mirrett S, Weinstein MP, Reimer LG, Wilson ML, Reller LB. Relevance of the number of positive bottles in determining clinical significance of coagulase-negative staphylococci in blood cultures. *J Clin Microbiol* 2001;39:3279–81.
- [37] Peacock SJ, Bowler IC, Crook DW. Positive predictive value of blood cultures growing coagulase-negative staphylococci. *Lancet* 1995;346:191–2.
- [38] Leyssene D, Gardes S, Vilquin P, Flandrois JP, Carret G, Lamy B. Species-driven interpretation guidelines in case of a single-sampling strategy for blood culture. *Eur J Clin Microbiol Infect Dis* 2011;30:1537–41.
- [39] Kassir C, Rangaraj G, Jiang Y, Hachem RY, Raad I. Differentiating culture samples representing coagulase-negative staphylococcal bacteremia from those representing contamination by use of time-to-positivity and quantitative blood culture methods. *J Clin Microbiol* 2009;47:3255–60.
- [40] Ruiz-Giardin JM, Martín-Díaz RM, Jaqueti-Aroca J, García-Arata I, San Martín-López JV, Sáiz-Sánchez Buitrago M. Diagnosis of bacteraemia and growth times. *Int J Infect Dis* 2015;41:6–10.
- [41] Congestri F, Pedra MF, Fantini M, Samuelli M, Schiavone P, Torri A, et al. Comparison of “time to detection” values between Bact/Alert Virtuo and

- Bact/Alert 3D instruments for clinical blood culture samples. *Int J Infect Dis* 2017;62:1–5.
- [42] Khatib R, Riederer KM, Clark JA, Khatib S, Briski LE, Wilson FM. Coagulase-negative staphylococci in multiple blood cultures: strain relatedness and determinants of same-strain bacteremia. *J Clin Microbiol* 1995;33:816–20.
  - [43] Kim SD, McDonald LC, Jarvis WR, McAllister SK, Jerris R, Carson LA, et al. Determining the significance of coagulase-negative staphylococci isolated from blood cultures at a community hospital: a role for species and strain identification. *Infect Control Hosp Epidemiol* 2000;21:213–7.
  - [44] Sharma M, Riederer K, Johnson LB, Khatib R. Molecular analysis of coagulase-negative *Staphylococcus* isolates from blood cultures: prevalence of genotypic variation and polyclonal bacteremia. *Clin Infect Dis* 2001;33:1317–23.
  - [45] Seo SK, Venkataraman L, DeGirolami PC, Samore MH. Molecular typing of coagulase-negative staphylococci from blood cultures does not correlate with clinical criteria for true bacteremia. *Am J Med* 2000;109:697–704.
  - [46] Papadimitriou-Olivieri I, Giormezis N, Papadimitriou-Olivieri M, Zotou A, Kolonitsiou F, Koutsileou K, et al. Number of positive blood cultures, biofilm formation, and adhesin genes in differentiating true coagulase-negative staphylococci bacteremia from contamination. *Eur J Clin Microbiol Infect Dis* 2016;35:57–66.
  - [47] Karakullukçu A, Kuşku MA, Ergin S, Aygün G, Midilli K, Küçükbasmacı Ö. Determination of clinical significance of coagulase-negative staphylococci in blood cultures. *Diagn Microbiol Infect Dis* 2017;87:291–4.
  - [48] Jordana-Lluch E, Giménez M, Quesada MD, Ausina V, Martró E. Improving the diagnosis of bloodstream infections: PCR coupled with mass spectrometry. *Biomed Res Int* 2014;2014:501214.
  - [49] Nagel JL, Huang AM, Kunapuli A, Gandhi TN, Washer LL, Lassiter J, et al. Impact of antimicrobial stewardship intervention on coagulase-negative *Staphylococcus* blood cultures in conjunction with rapid diagnostic testing. *J Clin Microbiol* 2014;52:2849–54.
  - [50] Osthoff M, Gürtler N, Bassetti S, Balestra G, Marsch S, Pargger H, et al. Impact of MALDI-TOF-MS–based identification directly from positive blood cultures on patient management: a controlled clinical trial. *Clin Microbiol Infect* 2017;23:78–85.
  - [51] Richter SS, Beekmann SE, Croco JL, Diekema DJ, Koontz FP, Pfaller MA, et al. Minimizing the workup of blood culture contaminants: implementation and evaluation of a laboratory-based algorithm. *J Clin Microbiol* 2002;40:2437–44.
  - [52] Elzi L, Babouee B, Vögeli N, Laffer R, Dangel M, Frei R, et al. How to discriminate contamination from bloodstream infection due to coagulase-negative staphylococci: a prospective study with 654 patients. *Clin Microbiol Infect* 2012;18:e355–61.
  - [53] García-Vázquez E, Fernández-Rufete A, Hernández-Torres A, Canteras M, Ruiz J, Gómez J. When is coagulase-negative *Staphylococcus* bacteraemia clinically significant? *Scand J Infect Dis* 2013;45:664–71.
  - [54] Rahkonen M, Luttinen S, Koskela M, Hautala T. True bacteremias caused by coagulase negative *Staphylococcus* are difficult to distinguish from blood culture contaminants. *Eur J Clin Microbiol Infect Dis* 2012;31:2639–44.
  - [55] Caldeira D, David C, Sampaio C. Skin antiseptics in venous puncture-site disinfection for prevention of blood culture contamination: systematic review with meta-analysis. *J Hosp Infect* 2011;77:223–32.
  - [56] Washer LL, Chenoweth C, Kim HW, Rogers MA, Malani AN, Riddell 4th J, et al. Blood culture contamination: a randomized trial evaluating the comparative effectiveness of 3 skin antiseptic interventions. *Infect Control Hosp Epidemiol* 2013;34:15–21.
  - [57] Story-Roller E, Weinstein MP. Chlorhexidine versus tincture of iodine for reduction of blood culture contamination rates: a prospective randomized crossover study. *J Clin Microbiol* 2016;54:3007–9.
  - [58] Martínez J, Macías JH, Arreguín V, Álvarez JA, Macías AE, Mosqueda-Gómez JL. Isopropyl alcohol is as efficient as chlorhexidine to prevent contamination of blood cultures. *Am J Infect Control* 2017;45:350–3.
  - [59] World Health Organization (WHO). Best practice in phlebotomy. WHO Guidelines; 2010. Available at: [http://www.euro.who.int/\\_data/assets/pdf\\_file/0005/268790/WHO-guidelines-on-drawing-blood-best-practices-in-phlebotomy-Eng.pdf](http://www.euro.who.int/_data/assets/pdf_file/0005/268790/WHO-guidelines-on-drawing-blood-best-practices-in-phlebotomy-Eng.pdf).
  - [60] Centers for Disease Control and Prevention. Clinician guide for collecting cultures. CDC Guidelines; 2015. Available at: <https://www.cdc.gov/getsmart/healthcare/implementation/clinicianguide.html>.
  - [61] Department of Health of the United Kingdom. Taking blood cultures: a summary of best practice. 2010. Available at: [http://webarchive.nationalarchives.gov.uk/20120118171812/http://hcai.dh.gov.uk/files/2011/03/Document\\_Blood\\_culture\\_FINAL\\_100826.pdf](http://webarchive.nationalarchives.gov.uk/20120118171812/http://hcai.dh.gov.uk/files/2011/03/Document_Blood_culture_FINAL_100826.pdf).
  - [62] Garcia RA, Spitzer ED, Beaudry J, Beck C, Diblasi R, Gilleeny-Blabac M, et al. Multidisciplinary team review of best practices for collection and handling of blood cultures to determine effective interventions for increasing the yield of true-positive bacteremias, reducing contamination, and eliminating false-positive central line–associated bloodstream infections. *Am J Infect Control* 2015;43:1222–37.
  - [63] Snyder SR, Favoretto AM, Baetz RA, Derzon JH, Madison BM, Mass D, et al. Effectiveness of practices to reduce blood culture contamination: a laboratory medicine best practices systematic review and meta-analysis. *Clin Biochem* 2012;45:999–1011.
  - [64] Self WH, Speroff T, McNaughton CD, Wright PW, Miller G, Johnson JG, et al. Blood culture collection through peripheral intravenous catheters increases the risk of specimen contamination among adult emergency department patients. *Infect Control Hosp Epidemiol* 2012;33:524–6.
  - [65] Kelly AM, Klim S. Taking blood cultures from a newly established intravenous catheter in the emergency department does not increase the rate of contaminated blood cultures. *Emerg Med Australas* 2013;25:435–8.
  - [66] Self WH, Speroff T, Grijalva CG, McNaughton CD, Ashburn J, Liu D, et al. Reducing blood culture contamination in the emergency department: an interrupted time series quality improvement study. *Acad Emerg Med* 2013;20:89–97.
  - [67] Self WH, Talbot TR, Paul BR, Collins SP, Ward MJ. Cost analysis of strategies to reduce blood culture contamination in the emergency department: sterile collection kits and phlebotomy teams. *Infect Control Hosp Epidemiol* 2014;35:1021–8.
  - [68] Denno J, Gannon M. Practical steps to lower blood culture contamination rates in the emergency department. *J Emerg Nurs* 2013;39:459–64.
  - [69] Ramirez P, Gordón M, Cortes C, Villarreal E, Perez-Belles C, Robles C, et al. Blood culture contamination rate in an intensive care setting: effectiveness of an education-based intervention. *Am J Infect Control* 2015;43:844–7.
  - [70] Alahmadi YM, McElroy JC, Kearney MP, Aldeyab MA, Magee FA, Hanley J, et al. Tackling the problem of blood culture contamination in the intensive care unit using an educational intervention. *Epidemiol Infect* 2015;143:1964–71.
  - [71] Bentley J, Thakore S, Muir L, Baird A, Lee J. A change of culture: reducing blood culture contamination rates in an emergency department. *BMJ Qual Improv Rep* 2016;5: u206760.w2754.
  - [72] Park WB, Myung SJ, Oh MD, Lee J, Kim NJ, Kim EC, et al. Educational intervention as an effective step for reducing blood culture contamination: a prospective cohort study. *J Hosp Infect* 2015;91:111–6.
  - [73] Baron EJ, Miller JM, Weinstein MP, Richter SS, Gilligan PH, Thomson Jr RB, et al. Executive summary: a guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). *Clin Infect Dis* 2013;57:485–8.
  - [74] Patton RG, Schmitt T. Innovation for reducing blood culture contamination: initial specimen diversion technique. *J Clin Microbiol* 2010;48:4501–3.
  - [75] Binkhamis K, Forward K. Effect of the initial specimen diversion technique on blood culture contamination rates. *J Clin Microbiol* 2014;52:980–1.
  - [76] Rupp ME, Cavalieri RJ, Marolf C, Lyden E. Reduction in blood culture contamination through use of initial specimen diversion device. *Clin Infect Dis* 2017;65:201–5.
  - [77] Poses RM, Anthony M. Availability, wishful thinking, and physicians' diagnostic judgments for patients with suspected bacteremia. *Med Decis Making* 1991;11:159–68.
  - [78] Eliakim-Raz N, Bates DW, Leibovici L. Predicting bacteraemia in validated models—a systematic review. *Clin Microbiol Infect* 2015;21:295–301.
  - [79] Arendrup M, Jensen IP, Justesen T. Diagnosing bacteremia at a Danish hospital using one early large blood volume for culture. *Scand J Infect Dis* 1996;28:609–14.
  - [80] Lamy B, Roy P, Carret G, Flandrois JP, Delignette-Muller ML. What is the relevance of obtaining multiple blood samples for culture? A comprehensive model to optimize the strategy for diagnosing bacteremia. *Clin Infect Dis* 2002;35:842–50.
  - [81] Dargère S, Parienti JJ, Roupie E, Gancel PE, Wiel E, Smaiti N, et al. Unique blood culture for diagnosis of bloodstream infections in emergency departments: a prospective multicentre study. *Clin Microbiol Infect* 2014;20:920–7.